drug

CDX-622

1 story · latest Aug 6, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Celldex Therapeutics

Timeline

Celldex reports Q2 2026 results as barzolvolimab Phase 3 enrollment finishes early

Aug 6Quarterly updatebarzolvolimab Celldex Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.